Estrella Immunopharma, Inc. ESLA
At closeNov 3, 2026, 7:44 PM EST
After hours · Nov 3, 7:44 PM ET
- YTD
- -73.21%
- 1 year
- -86.30%
- Market cap
- 18.18M
- EPS (ttm)
- -0.24
- Shares out
- 36.18M
- YTD return
- -73.21%
- 1-year return
- -86.30%
- Volume
- 526.28K
- Avg volume
- 1.79M
- Open
- 0.429
- Previous close
- 0.4263
- Day's range
- 0.3517 – 0.475
- 52-week range
- 0.314 – 3.05
- Beta
- 0.24
2Y -0.3650 (-46.62%)
Key statistics
- Enterprise value
- 28.05M
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 9.58
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -12.95M
- Total cash
- 4.17M
- Total debt
- 4.00K
- Return on equity
- 0.00%
- Short % of float
- 0.06%
- 50-day average
- 0.97534
- 200-day average
- 1.10
Next earnings
Consensus EPS estimate 0.00.
Financials — quick view
About Estrella Immunopharma, Inc.
Estrella Immunopharma, Inc., a clinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidates include EB103, which is in clinical trial, for the treatment of diffuse large B-cell lymphoma; EB104, which is in pre-clinical trial, to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia; and EB201, which is in pre-clinical trial, for the treatment of systemic lupus erythematosus. It has a collaborative agreement with Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103. Estrella Immunopharma, Inc. was founded in 2006 and is headquartered in EmeryVille, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- estrellabio.com
News
Estrella Immunopharma Appoints Cynthia Pussinen CEO, Chairperson, Effective Oct. 25, Succeeding Cheng Liu 
Estrella Immunopharma Appoints Cynthia Pussinen as Chief Executive Officer and Chairperson of the Board of Directors 
12 Health Care Stocks Moving In Friday's Intraday Session 
12 Health Care Stocks Moving In Thursday's After-Market Session 
12 Health Care Stocks Moving In Thursday's Intraday Session 
Estrella Immunopharma (ESLA) Stock Soars 18%: What’s Driving the Surge - 12 Health Care Stocks Moving In Wednesday's Intraday Session
12 Health Care Stocks Moving In Monday's Intraday Session - 12 Health Care Stocks Moving In Monday's Pre-Market Session
Estrella Immunopharma Treats First Patient with Two EB103 Infusions in STARLIGHT-1 Dose-Expansion Phase
Your note
Sign in to keep a note on ESLA — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Geode Capital Management, LLC | 0.21% | 76,556 | 86.51K | Sep 29, 2024 |
| ATW Spac Management LLC | 0.11% | 40,000 | 45.20K | Sep 29, 2024 |
| Blackrock Inc. | 0.07% | 24,963 | 28.21K | Sep 29, 2024 |
| Vanguard Group Inc | 0.06% | 21,684 | 24.50K | Sep 29, 2024 |
| Citadel Advisors Llc | 0.04% | 14,531 | 16.42K | Sep 29, 2024 |
| Maso Capital Partners Ltd. | 0.03% | 10,000 | 11.30K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity Extended Market Index Fund | 0.16% | 56,779 | 64.16K | Oct 30, 2024 |
| iShares Micro Cap ETF | 0.06% | 22,435 | 25.35K | Oct 30, 2024 |
| Vanguard Total Stock Market Index Fund | 0.05% | 17,968 | 20.30K | Sep 29, 2024 |
| Fidelity Total Market Index Fund | 0.05% | 16,862 | 19.05K | Oct 30, 2024 |
| Fidelity Series Total Market Index Fund | 0.04% | 13,413 | 15.16K | Oct 30, 2024 |
| EQ Advisors Trust-1290 VT Micro Cap Port | 0.01% | 2,373 | 2.68K | Sep 29, 2024 |